Cell proliferation-related markers in colorectal liver metastases: Correlation with patient prognosis
Cell proliferation-related markers in colorectal liver metastases: Correlation with patient prognosis
复制标题
DOI：
10.1200/jco.1997.15.5.2008
复制
发表时间：
1997-05-01
影响因子：
45.3
通讯作者：
Silvestrini, R
中科院分区：
文献类型：
--
作者：
Costa, A;Doci, R;Silvestrini, R
目的：我们分析了表型与（DNA倍性）和功能标记（S期细胞分数、p53和bcl-2蛋白表达）并定义它们与结直肠癌根治性切除肝转移的回顾性系列临床结果的相关性。对104例可切除的结直肠癌肝转移患者，采用流式细胞术检测DNA倍体，用放射自显影法测定H-3-胸苷标记指数（TLI），用免疫组化法测定p53和bcl-2的表达。TLI是根治术后4年复发的重要指标，DNA倍体是临床结果的提示性指标，而p53和bcl-2表达没有提供临床信息。通过多变量分析，在最具代表性的H-1肝病变患者亚组中，细胞增殖率和Dukes分期仍然是独立的预后参数，86例中，TLI与复发有关，DNA倍体和p53表达可作为鉴别慢增殖性肝损害的依据。肝病变的肿瘤细胞增殖应与原发性结直肠癌的分期一起使用，以便在接受根治性肝切除术的患者中获得更准确的预后，（C）1997年由美国临床肿瘤学会。
Purpose: We analyzed the relation between phenotypic (DNA ploidy) and functional markers (S-phase cell fraction, p53, and bcl-2 protein expression) and defined their relevance on clinical outcome on a retrospective series of radically resected liver metastases from colorectal cancer.Patients and Methods: Among 104 patients with resectable liver metastases from colorectal cancer, DNA ploidy was determined by flow cytometry, H-3-thymidine labeling index (TLI) by autoradiography, and expression of p53 and bcl-2 by immunohistochemistry.Results: TLI was a significant indicator for relapse at 4 years from radical surgery, DNA ploidy was a suggestive indicator of clinical outcome, and p53 and bcl-2 expression provided no clinical information, By multivariate analysis, cell proliferation rate and Dukes' stage remained independent prognostic parameter, In the most representative subgroup of patients with H-1 liver lesions (86 cases), TLI was always associated with relapse, and DNA ploidy and p53 expression provided discriminant information within slowly proliferating liver lesions,Conclusion: Tumor-cell proliferation of liver lesions should be used with stage of the primary colorectal cancer for a more accurate prognosis in patients submitted to curative hepatic resection, (C) 1997 by American Society of Clinical Oncology.